Orphalan Acquires Orphelia Pharma

Orphalan is an international pharmaceutical company focused on the development, regulatory approval, and commercialization of orphan drug medicines for rare and often serious diseases where treatment options are limited. The Company’s portfolio includes products such as trientine tetrahydrochloride for Wilson’s disease, marketed in multiple countries under brands like Cuprior and Cuvrior, and conducts global clinical research programs while expanding patient access through partnerships and new market launches. Orphalan was founded in 2011 and is headquartered in Paris, France, with commercial and corporate offices in Malta and the United States.